Long non-coding RNA <i>UCA1</i> induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in <i>EGFR</i>-mutant non-small cell lung cancer

Ningning Cheng(Tongji University), Fred R. Hirsch(University of Colorado Anschutz Medical Campus), Caicun Zhou(Tongji University), Fei Ke(Shanghai Pulmonary Hospital), Xuefei Li(Chengdu University of Traditional Chinese Medicine), Hui Pan(Inserm), Jiayu Li(Tongji University), Chao Zhao(Tongji University), Xiaoxia Chen(Tongji University), Qi Wang(Tongji University), Weijing Cai(Icahn School of Medicine at Mount Sinai), Shengxiang Ren(Tongji University), Mingchuan Zhao(Tongji University), Yishi Zhang(Tongji University)
Oncotarget
June 8, 2015
10.18632/oncotarget.4361
Cited by 149

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467